Opus Genetics
IRD
103 hedge funds and large institutions have $236M invested in Opus Genetics in 2026 Q2 according to their latest regulatory filings, with 40 funds opening new positions, 34 increasing their positions, 12 reducing their positions, and 16 closing their positions.
183% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 12
150% more first-time investments, than exits
New positions opened: 40 | Existing positions closed: 16
30% more funds holding
Funds holding: 79 → 103 (+24)
16% more capital invested
Capital invested by funds: $204M → $236M (+$32.6M)
5.83% more ownership
Funds ownership: 63.83% → 69.66% (+5.8%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$13.8M |
| 2 |
TECP
Trails Edge Capital Partners
Atlanta,
Georgia
|
+$10.5M |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$7.68M |
| 4 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$6.44M |
| 5 |
Goldman Sachs
New York
|
+$5.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$8.35M |
| 2 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$4.55M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$2.92M |
| 4 |
MBAM
Mink Brook Asset Management
West Palm Beach,
Florida
|
-$2M |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
-$1.77M |
IRD Hedge Fund Activity: Q2 2026 in Review
103 of the 8,318 institutional investors tracked by Wall St. Rank reported a position in Opus Genetics (IRD) for Q2 2026, worth a combined $236M — up 16% from $204M a quarter earlier.
Buyers outnumbered sellers: 40 funds opened new IRD positions and 16 closed out — a net gain of 24 holders — while 34 added to existing stakes and 12 trimmed.
The largest buyer was BlackRock, adding an estimated $13.8M. The largest seller was Perceptive Advisors, exiting entirely with an estimated $8.35M sold.
- 103 institutional investors held Opus Genetics (IRD) as of Q2 2026, up from 79 in Q1 2026.
- Funds reported $236M of Opus Genetics stock for Q2 2026, up 16% quarter-over-quarter.
- 40 funds opened new Opus Genetics positions in Q2 2026 and 16 closed out, a net change of +24 holders.
- The largest Opus Genetics buyer in Q2 2026 was BlackRock, an estimated $13.8M added.
- The largest Opus Genetics seller in Q2 2026 was Perceptive Advisors, an estimated $8.35M sold.
Based on aggregated 13F filings for Q2 2026.